INFLIXIMAB FOR TREATMENT OF COPD - A PILOT STUDY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic obstructive pulmonary disease (COPD) is a devasting complication of cigarette smoking. In addition to severe problems in lung function, there is evidence that inflammation plays a major role in leading to disability in COPD. Elevation of an inflammatory factor in COPD, tumor necrosis factor alpha (TNFa), could cause severe weight loss, muscle weakness and wasting. These findings are a grave sign in COPD patients. We will be performing a pilot study on 12 COPD patients using a drug called infliximab, an antibody against TNF-alpha. We will be monitoring adverse events and a number of outcomes that could indicate clinical improvement. These include lung function, muscle strength, exercise performance, body composition, and quality of life. Data gathered from this pilot study will be used to design a randomized clinical trial of a novel new therapy for COPD in a larger group of patients.